Description
Springer Ovarian Cancers Advances Through International Research Cooperation 2016 Edition by Eric Pujade-Lauraine Isabelle Ray-Coquard
This book provides an overview of the latestdevelopments in the concepts and management of ovarian cancer. The new datapresented throughout opens the way to radically different therapeuticapproaches. Surgery remains the core of ovarian cancer treatment but itsultimate goal and the standard surgical procedure have evolved giving rise tothe question of how to label expert centers for debulking surgery. Neo-adjuvantchemotherapy is becoming more popular and is also a new field for testing noveldrug combinations.Over recent years ovarian cancer managementhas embraced molecular biology. It is now more correct to talk about cancers ofthe ovary rather than ovarian cancer since it is not a unique disease butseveral entities with different molecular drivers. The significant advances indrugs targeting the microenvironment or the tumor cell DNA repair mechanismsare presented in detail together with exciting future perspectives.All these advances would not have been possiblewithout collaborative groups such as the GINECO group in France and theirintegration in wider clinical research networks at the European (ENGOT) andinternational (GCIG) level. Table of contents : PART 1: OVARIAN CANCER MANAGEMENTChapter 1. Clinical research in Europe dedicated to ovarian cancersE. Pujade-Lauraine Paris France Chapter 2. Genetics of ovarian carcinomasClaire Senechal Bruno Buecher Antoine de Pauw Claude Houdayer Etienne Rouleau Catherine Nogues Dominique Stoppa-LyonnetChapter 3. Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality Fabrice Lecuru Charlotte Ngo Anne Sophie Bats Cherazade Bensaid Pierre Combe Eric Pujade Lauraine Marie Aude le Frere Belda Laure FournierChapter 4. How to evaluate tumor burden before therapeutic decisionA. Fagotti L. Pedone Anchora M. Pacciani G. ScambiaChapter 5. Value of lymphadenectomyPhilipp Harter Florian Heitz Andreas du BoisChapter 6. HYPEC: what is the evidence? Jean-Marc ClasseChapter 7. Onco-fertility applied to ovarian cancersEnrica Bentivegna Sebastien Gouy Catherine Uzan Marcos Ballester Catherine Poirot Emile Darai Philippe MoriceChapter 8. First-line systemic therapy (chemo/antiangiogenics) Sandro Pignata Sabrina Cecere Chapter 9.Elderly C. Falandry Lyon FranceChapter 10. Treatment at relapse (surgery & Systemic treatments)J. Pfisterer A. FloquetChapter 11. The future in ovarian cancers & place of the new immunotherapies in ovarian cancersHolbrook E.K. Kohrt Amani Makkouk Cariad ChesterPART 2: PARTICULAR TYPES OF OVARIAN CANCERS (for each: histology and molecular specificities specificity for surgery and management in first line and relapse)Chapter 12. High Grade Carcinomas BRCA mutations and the role of PARP inhibitorsJonathan A LedermannChapter 13. Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or PeritoneumDavid M. GershensonChapter 14. Clear Cell carcinomaMasashi Takano Satoshi Takakura Keiichii FujiwaraChapter 15. Endometrioid carcinoma Laure de Cock Gerlinde Averous Philippe Barthelemy Jean-Emmanuel KurtzChapter 16. Mucinous carcinomaJubilee Brown MD AndersonChapter 17. Uterine and Ovarian CarcinosarcomaD. Berton-Rigaud JS Frenel I Ray-CoquardChapter 18. Malignant Ovarian Germ Cell Tumours; an overview of management and controversiesDr Costi Alifrangis Professor Michael J SecklGarbi Annalisa Achilarre Maria Teresa Colombo NicolettaChapter 20. Very rare ovarian malignant tumors including small cell carcinoma Patricia Pautier